Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LIG1 | P18858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484361 | 0.92 | KDM4E (0.66) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL9305217 | 0.92 | KDM4E (0.74) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL29537569 | 0.92 | KDM4E (0.74) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL18374475 | 0.86 | KDM4E (0.51) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL15312851 | 0.85 | KDM4E (0.60) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL27908918 | 0.84 | KDM4E (0.50) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL9525514 | 0.84 | KDM4E (0.50) | KDM4EGAATSHRKMT2AALDH1A1 | |
| SCHEMBL3319699 | 0.84 | GAA (0.65) | KDM4EGAATSHRCREBBPLIG1 | |
| SCHEMBL9130664 | 0.83 | KDM4E (0.58) | KDM4EPDE4BPOLBGAATSHR | |
| SCHEMBL13690626 | 0.82 | KDM4E (0.57) | KDM4EPDE4BPOLBGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11953833-B2 | Compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and transistor production method | NIKON CORPORATION (JP) | 2024-04-09 | — | — | US | disclosed |
| CN-111183143-B | Compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and method for manufacturing transistor | 株式会社 尼康 | 2023-04-04 | — | — | CN | disclosed |
| US-20200233304-A1 | COMPOUND, SUBSTRATE FOR PATTERN FORMATION, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMATION METHOD, AND TRANSISTOR PRODUCTION METHOD | NIKON CORPORATION (JP) | 2020-07-23 | — | — | US | disclosed |
| US-20200233304-A1 | COMPOUND, SUBSTRATE FOR PATTERN FORMATION, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMATION METHOD, AND TRANSISTOR PRODUCTION METHOD | NIKON CORPORATION (JP) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11953833-B2 | Compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and transistor production method | CYP1A1, CYP1A2, CYP1B1 | KDM4E 4675/4885PDE4B 3422/4885POLB 1448/4885 |
| US-20200233304-A1 | COMPOUND, SUBSTRATE FOR PATTERN FORMATION, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMATION METHOD, AND TRANSISTOR PRODUCTION METHOD | CYP1A1, CYP1A2, CYP1B1 | KDM4E 4675/4885PDE4B 3422/4885POLB 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.